Glaukos Corporation GKOS Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$224.41 up $4.43, 2.01% at close Nov 6
Last close · Previous close $219.98
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.95Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$224.41up $4.43, 2.01%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$219.98Nov 5
- Volume1.20MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.88MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $83.78 to $255.19; now $224.41
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
GKOS beat the S&P 500 in all 7 periods.
| Period | GKOS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GKOS: up 38.9% S&P 500: down 5.6% | GKOS beat the S&P 500 by 44.5 percentage points Beat |
| 3M | GKOS: up 31.2% S&P 500: down 4.1% | GKOS beat the S&P 500 by 35.3 percentage points Beat |
| YTD | GKOS: up 98.8% S&P 500: up 8.7% | GKOS beat the S&P 500 by 90.1 percentage points Beat |
| 1Y | GKOS: up 174.4% S&P 500: up 10.9% | GKOS beat the S&P 500 by 163.5 percentage points Beat |
| Long term | ||
| 3Y | GKOS: up 250.6% S&P 500: up 75.0% +51.9% vs +20.5% a year | GKOS beat the S&P 500 by 175.6 percentage points Beat |
| 5Y | GKOS: up 293.8% S&P 500: up 67.8% +31.5% vs +10.9% a year | GKOS beat the S&P 500 by 226.0 percentage points Beat |
| 10Y | GKOS: up 598.2% S&P 500: up 313.1% +21.5% vs +15.2% a year | GKOS beat the S&P 500 by 285.1 percentage points Beat |
$10,000 invested in GKOS 10 years ago (Nov 4, 2016) would be worth about $69,823 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
GKOS beat the S&P 500 in all 7 periods.
| Period | GKOS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | GKOS: up 38.9% S&P 500: down 5.6% | GKOS beat the S&P 500 by 44.5 percentage points Beat |
| 3M | GKOS: up 31.2% S&P 500: down 4.3% | GKOS beat the S&P 500 by 35.5 percentage points Beat |
| YTD | GKOS: up 98.8% S&P 500: up 7.8% | GKOS beat the S&P 500 by 91.0 percentage points Beat |
| 1Y | GKOS: up 174.4% S&P 500: up 9.7% | GKOS beat the S&P 500 by 164.7 percentage points Beat |
| Long term | ||
| 3Y | GKOS: up 250.6% S&P 500: up 68.8% +51.9% vs +19.1% a year | GKOS beat the S&P 500 by 181.8 percentage points Beat |
| 5Y | GKOS: up 293.8% S&P 500: up 56.9% +31.5% vs +9.4% a year | GKOS beat the S&P 500 by 236.9 percentage points Beat |
| 10Y | GKOS: up 598.2% S&P 500: up 252.6% +21.5% vs +13.4% a year | GKOS beat the S&P 500 by 345.6 percentage points Beat |
$10,000 invested in GKOS 10 years ago (Nov 4, 2016) would be worth about $69,823 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$246.70
Closing high on . Now 9.0% below that record.
Split-adjusted daily closes since Jun 25, 2015.
Stock splits
GKOS hasn’t split since its price history begins in 2015.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $690.33Mup 46.9%
- Net income
- −$169.80M
- Diluted EPS
- −$2.95
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $105.50M | −$33.58M | −$0.59 |
| Q1 FY25 (Mar 31, 2025) | $106.66M | −$18.15M | −$0.32 |
| Q2 FY25 (Jun 30, 2025) | $124.12M | −$19.66M | −$0.34 |
| Q3 FY25 (Sep 30, 2025) | $133.54M | −$16.23M | −$0.28 |
| Q4 FY25 (Dec 31, 2025) | $143.12M | −$133.66M | −$2.33 |
| Q1 FY26 (Mar 31, 2026) | $150.57M | −$19.78M | −$0.34 |
| Q2 FY26 (Jun 30, 2026) | $185.61M | −$18.38M | −$0.31 |
| Q3 FY26 (Sep 30, 2026) | $211.03M | $2.02M | $0.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $294.01M | −$49.59M | −$1.07 |
| FY22 (Dec 31, 2022) | $282.86M | −$99.20M | −$2.09 |
| FY23 (Dec 31, 2023) | $314.71M | −$134.66M | −$2.78 |
| FY24 (Dec 31, 2024) | $383.48M | −$146.37M | −$2.77 |
| FY25 (Dec 31, 2025) | $507.44M | −$187.69M | −$3.28 |
Margins
- Gross 64.8%
- Operating −25.5%
- Net −24.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $36.02MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$47.71MLast 12 months
- Capital spending$11.69MLast 12 months
- 5.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $44.32MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $339.81MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$101.98MAs of Sep 30, 2026
- Net cash$237.83MAs of Sep 30, 2026
- 4.57As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.14As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −24.9%Last 12 months
Over the last 12 months, Glaukos lost money: its net loss was 24.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −18.4%Last 12 months
Over the last 12 months, Glaukos’s net loss was 18.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Glaukos Corporation
Glaukos ( www.glaukos.com ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
GKOS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GKOS stock FAQ
What is GKOS stock’s price today?
Glaukos (GKOS) traded at $224.41 at the close on , up $4.43 (2.01%) from the previous close of $219.98. Over the past 52 weeks it has traded between $83.78 and $255.19.
If you invested $1,000 in GKOS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in GKOS on would be worth about $6,982 at the close on , a total return of +598.2%. The same $1,000 would be worth $3,938 if invested five years ago and $2,744 if invested one year ago. Past performance doesn’t predict future returns.
What is GKOS’s P/E ratio?
GKOS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.95).
How much revenue does Glaukos make?
Glaukos reported $690.3 million of revenue over the four quarters to , up 46.9% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $211.0 million, up 58.0% from a year earlier.
Is Glaukos profitable?
Not over the four quarters to . Glaukos reported a net loss of $169.8 million across those four quarters on $690.3 million of revenue.
What are GKOS’s earnings per share?
GKOS’s diluted earnings per share were −$2.95 over the four quarters to , compared with −$1.53 in the twelve months before. The latest quarter (Q3 FY26) brought $0.03 per share, against −$0.28 a year earlier (how EPS works).
Does GKOS pay a dividend?
Glaukos hasn’t paid a dividend in the last twelve months.
What is GKOS’s 52-week high and low?
Over the past 52 weeks GKOS has traded as low as $83.78 and as high as $255.19. At $224.41 at the close on , it is 12.1% below that high and 167.9% above the low.
What is GKOS’s all-time high?
GKOS’s highest closing price was $246.70 on , adjusted for stock splits. At $224.41 at the close on , it is 9.0% below that record.
Has GKOS stock ever split?
No. GKOS hasn’t split since its price history begins in 2015.
How has GKOS stock performed?
Including dividends and measured to the close on , GKOS has returned +98.8% so far this year and +174.4% over the past year, and +293.8% over five years (+31.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Glaukos in?
Glaukos is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does GKOS trade on?
Glaukos trades on the NYSE under the ticker symbol GKOS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.